These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38623708)

  • 21. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
    Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-life experience study of the safety and efficacy of travoprost 0.004% / timoptol 0.50% fixed combination ophthalmic solution in intraocular pressure control.
    Olali C; Malietzis G; Ahmed S; Samaila E; Gupta M
    Niger J Clin Pract; 2011; 14(1):29-33. PubMed ID: 21493988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis.
    Xing Y; Zhu L; Zhang K; Huang S
    PLoS One; 2020; 15(2):e0229682. PubMed ID: 32106236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews.
    Daka Q; Trkulja V
    Croat Med J; 2014 Oct; 55(5):468-80. PubMed ID: 25358880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components.
    Konstas AG; Katsimpris IE; Kaltsos K; Georgiadou I; Kordelou A; Nelson LA; Stewart WC
    Eye (Lond); 2008 Nov; 22(11):1391-7. PubMed ID: 17571086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension.
    Natt NK; Gupta A; Singh G; Singh T
    Indian J Ophthalmol; 2014 Dec; 62(12):1136-40. PubMed ID: 25579357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years.
    Rouland JF; Le Pen C; Benhaddi H; Piriou E; Lilliu H; Kenigsberg PA;
    Eur J Ophthalmol; 2005; 15(5):562-80. PubMed ID: 16167287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/ timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension.
    Pachimkul P; Yuttitham K; Thoophom P
    J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S81-7. PubMed ID: 21717884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.
    Schuman JS; Katz GJ; Lewis RA; Henry JC; Mallick S; Wells DT; Sullivan EK; Landry TA; Bergamini MV; Robertson SM
    Am J Ophthalmol; 2005 Aug; 140(2):242-50. PubMed ID: 16086946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Bimatoprost Plus Timolol Fixed Combination in Open Angle Glaucoma Patients Previously Treated with Dorzolamide Plus Timolol Fixed Combination.
    Sacchi M; Specchia C; Williams SE; Villani E; Nucci P
    Curr Eye Res; 2016 Nov; 41(11):1433-1437. PubMed ID: 27115319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: multicenter, open-label, observational study in Germany.
    Thelen U; Buchholz P; Kimmich F
    Curr Med Res Opin; 2009 Apr; 25(4):1003-9. PubMed ID: 19275517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination.
    Alezzandrini A; Hubatsch D; Alfaro R
    Adv Ther; 2014 Sep; 31(9):975-85. PubMed ID: 25138224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination.
    Sellem E; Rouland JF; Baudouin C; Bron A; Denis P; Nordmann JP; Renard JP
    BMC Ophthalmol; 2010 Mar; 10():10. PubMed ID: 20346127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients.
    Aihara M; Adachi M; Matsuo H; Togano T; Fukuchi T; Sasaki N;
    Acta Ophthalmol; 2017 Dec; 95(8):e720-e726. PubMed ID: 28371482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.
    Khouri AS; Serle JB; Bacharach J; Usner DW; Lewis RA; Braswell P; Kopczynski CC; Heah T;
    Am J Ophthalmol; 2019 Aug; 204():97-104. PubMed ID: 30862500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol.
    García-Feijoó J; Sáenz-Francés F; Martínez-de-la-Casa JM; Méndez-Hernández C; Fernández-Vidal A; Calvo-González C; García-Sánchez J
    Curr Med Res Opin; 2010 Jul; 26(7):1599-606. PubMed ID: 20429818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma.
    Kim JM; Kim TW; Park SW; Park HL; Hwang YH; Jeoung JW; Kim CY
    Semin Ophthalmol; 2021 Apr; 36(3):103-109. PubMed ID: 33734910
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2).
    Bacharach J; Tatham A; Ferguson G; Belalcázar S; Thieme H; Goodkin ML; Chen MY; Guo Q; Liu J; Robinson MR; Bejanian M; Wirta DL;
    Drugs; 2021 Nov; 81(17):2017-2033. PubMed ID: 34724172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.